Articles scientifiques

Emerging targeted agents in metastatic breast cancer.

Auteurs : Zardavas D, Baselga J, Piccart-Gebhart M
Année : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(4)
Pages : 191-210

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Auteurs : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Année : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2897-902

Stratified Medicine: a call for action

Auteurs : Awada A, Annemans L, Broeckx D, Pauwels P, Simoens S, Van Belle S, van Cutsem E, Van Hoof E, De Greve J
Année : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pages : 15-19

Personalized therapy for breast cancer: a dream or a reality?

Auteurs : Zardavas D, Pugliano L, Piccart-Gebhart M
Année : 2013
Journal : Future Oncol
Volume : 9(8)
Pages : 1105-19

Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial.

Auteurs : Azim HA, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart-Gebhart M, de Azambuja E
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(36)
Pages : 4504-11

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Auteurs : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Année : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pages : 2621-32

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Auteurs : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Année : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5

Personalised cancer management: closer, but not here yet.

Auteurs : Piccart-Gebhart M
Année : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1951-5

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Auteurs : Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, + collaborators (among others :, Hannah AL, Perez EA
Année : 2013
Journal : Lancet Oncol
Volume : 14(12)
Pages : 1216-25

Stratified medicine: a call for action.

Auteurs : Jacob I, Awada A, Payne K, Annemans L
Année : 2013
Journal : Expert Rev Pharmacoecon Outcomes Res
Volume : 13(3)
Pages : 277-9

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Auteurs : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Année : 2013
Journal : Adv Ther
Volume : 30(10)
Pages : 870-84

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Auteurs : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Année : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Breast Cancer. Side Effects of Medical Cancer Therapy: Prevention and Treatment. Ed. Mario A. Dicato. Chapter 2: P29-117; Springer 2013, XIII.

Auteurs : Aftimos P, Gombos A, Pugliano L, Awada A, Piccart-Gebhart M
Année : 2013
Journal : Book
Volume : chapter2
Pages : P29-117

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Auteurs : Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart-Gebhart M, Harbeck N
Année : 2012
Journal : Breast Cancer Res. Treat.
Volume : 134(3)
Pages : 1149-59

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Auteurs : Berghmans T, Remmelink M, Awada A
Année : 2012
Journal : Lung Cancer : Targets and Therapy
Volume : 3
Pages : 91-99

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

Auteurs : Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G
Année : 2012
Journal : Breast
Volume : 21(1)
Pages : 20-6

Understanding the biology of triple-negative breast cancer.

Auteurs : Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C
Année : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pages : vi13-vi18

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Auteurs : Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L
Année : 2012
Journal : Breast
Volume : 21(4)
Pages : 507-13

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.

Auteurs : Azim H, Azim HA
Année : 2012
Journal : Future Oncol
Volume : 8(2)
Pages : 135-44

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Auteurs : Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ
Année : 2012
Journal : Lancet Oncol
Volume : 13(9)
Pages : 897-905